| 19F | Fluorine-19 |
| ATMP | advanced therapy medicinal product |
| BMI | body-mass index |
| CXCL12 | C-X-C Motif Chemokine Ligand 12 |
| D2R | dopamine 2 receptors |
| DOA | detrusor overactivity |
| DTI | diffusion tensor imaging |
| EUS | external urethral sphincter |
| FDA | Food and Drug Administration |
| GCP | good clinical practice |
| GMP | good manufacturing practice |
| ICIQ | International Consultation on Incontinence Questionnaire |
| ICIQ-SF | International Consultation on Incontinence Questionnaire–Short Form |
| ICS | International Continence Society |
| ISD | intrinsic sphincter deficiency |
| LPP | leak point pressure |
| MDSC | muscle-derived stem cell |
| MPC | muscle progenitor cell |
| MRI | magnetic resonance imaging |
| MSC | mesenchymal stromal cell |
| MT | magnetization transfer |
| MUCP | maximal urethral closure pressure |
| NMES | neuromuscular electromagnetic stimulation |
| pADSC | porcine adipose tissue-derived stromal cell |
| PET | positron emission tomography |
| PRO | patient reported outcome |
| QoL | quality of life |
| SPIO | superparamagnetic iron oxide |
| SSNRI | selective serotonin noradrenaline inhibitors |
| SUI | stress urinary incontinence |
| TE | tissue engineering |
| TVT | tension free vaginal tape |
| UI | urinary incontinence |
| VLPP | Valsalva leak point pressure |
| µCT | micro-computed tomography |